1. Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract 15. 486826/477169/465253/454771/4406110/4146 489829/481554/473347/464656/4510112/4219 HR 0.81 (0.67-0.98; P<0.03) Probability 0.00 0.02 0.04 0.06 0.08 0.10 Years since randomization 0.00.51.01.52.02.5 Tamoxifen Exemestane

2. DFS: On-Study Drug and Pre-Switch — Excluding 96 Never Treated Patients Numbers at risk: Tamoxifen:481728/451072/420763/396271/366487/2817 Exemestane:485333/455264/434353/421047/4067114/3779 Cumulative probability HR 0.83 (95% CI 0.71-0.97, P=0.02) Probability 0.00 0.02 0.04 0.06 0.08 0.10 Years since randomization 0.00.51.01.52.02.5 Tamoxifen Exemestane Adapted from Jones et al. SABCS 2008, abstract 15.

3. 3 AI events* (%)TAM events* (%) Annual event ratio (AI:TAM) P value (trend) Cohort 1 (AI upfront vs. TAM) Years 0-1163/4954 (3.3)234/4902 (4.8)0.67 >0.1; NS Years 2-4261/4670 (5.6)307/4557 (6.7)0.81 Years ≥5160/2939 (5.4)180/2803 (6.4)0.83 Cohort 2 (AI switch vs. TAM) Years 0-2 † 187/4508 (4.1)303/4507 (6.7)0.60 0.003 Years ≥3 † 172/2978 (5.8)177/2854 (6.2)0.92 *Events per woman entering time period. † Time since allocated treatment differed. Recurrence According to Time Adapted from Jones et al. SABCS 2008, abstract 15.

4. Breast cancer mortality, % Death without recurrence, %Any death, % Cohort 1 (AI upfront vs. TAM) 5-year data 4.8 vs. 5.9 (1.1% AI gain) 4.4 vs. 4.2 (0.2% AI loss) 8.8 vs. 9.6 (0.8% AI gain) 8-year data 10.0 vs. 10.5 (0.5% AI gain); P=0.1 9.1 vs. 8.8 (0.3% AI loss); P=0.9 17.8 vs. 18.0 (0.2% AI gain); P=0.3 Cohort 2 (AI switch vs. TAM) 3-year data* 1.4 vs. 2.4 (0.7% AI gain) 1.7 vs. 2.1 (0.4% AI gain) 3.3 vs. 4.4 (1.1% AI gain) 6-year data* 6.3 vs. 8.0 (1.6% AI gain); P=0.02 5.0 vs. 5.7 (0.7% AI gain); P=0.08 10.8 vs. 13.0 (2.2% AI gain); P=0.004 Breast Cancer Mortality, Death Without Recurrence, and Any Death Data *Time since allocated treatment differed. Adapted from Jones et al. SABCS 2008, abstract 15.